Malaria Clinical Trial
— Pro-CCMOfficial title:
Randomized Cluster Trial to Measure the Effectiveness of Home Care in Hyperendemic Rural Areas in Madagascar
Verified date | January 2022 |
Source | Institut Pasteur de Madagascar |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The trial took place in a rural area hyper endemic for malaria, the hypothesis of which was that active detection and treatment of malaria in the population (all ages combined) in the event of a positive test could reduce the prevalence of malaria in the region. zoned. It was a two-armed, randomized, cluster-based community intervention trial: - one arm with home treatment of malaria for the duration of the study for patients with a positive result in the rapid diagnostic test for malaria. - a control arm with the usual malaria management procedures (ie consultation with community workers or the nearest health centers in the event of fever or suspected signs of malaria). Before the start of monitoring, an initial survey (Baseline) was carried out in the "fokontany" (villages / cluster) included in the 2 arms, in order to determine the prevalence of malaria. Then, in the intervention arm, screening for malaria by RDT every 2 weeks in subjects with a suspected malaria case (fever or notion of fever in the 2 days preceding the visit) and treatment with Artesunate-amodiaquine (ACT) for patients with a positive RDT. At the end of the follow-up period, a final survey (Endline), based on the same questionnaires as during the Baseline, was carried out in the 2 villages of the 2 arms. As a secondary objective, a study on anemia in women aged between 15 and 49 years was also carried out during the baseline and endline periods in order to compare the prevalence between the 2 periods
Status | Completed |
Enrollment | 1000 |
Est. completion date | December 29, 2018 |
Est. primary completion date | December 12, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Months and older |
Eligibility | Inclusion Criteria: - Inclusion criteria in community: - Fokontany in rural communes of Mananjary district (fokontany level of safety, accessibility by the study teams, and phone network availability was assessed). - Agreement of the chief of Fokontany for the participation of his fokontany in the study - Fokontany with at least 1,000 inhabitants - Individual inclusion criteria: - Resident in the relevant areas during the study period and consenting to participate Exclusion Criteria: - Exclusion criteria in community: - Fokontany with a total population of less than 1000 inhabitants - Fokontany in an urban commune - Fokontany in an area whose access is risky and perilous - Individual exclusion criteria: None (Non-resident present at the time of passage were tested in the study if they have suggestive signs of malaria but they were considered as visitors) |
Country | Name | City | State |
---|---|---|---|
Madagascar | Fokontany Ambakoana | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambalamanasa | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambalaromba | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambinany Namorona | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Amboditandroho | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambohimiarina II | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambohinihaonana | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ambolotara | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Andranomavo | Mananjary | : Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Andranomiteka | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Anilavinany | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Ankazotokana | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Anosimparihy | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Kianjavato | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Mahavoky Sud | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Manotro | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Maroamboka | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Sahafotahina | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Sandravakoka | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Tanambao Sud | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Tanambaobe | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Madagascar | Fokontany Tsarahafatra | Mananjary | Fianarantsoa, Vatovavy Fitovinany |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur de Madagascar | National Malaria Control Programme, Madagascar, Peace Corps, United States Agency for International Development (USAID) |
Madagascar,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint of the study was the change in the prevalence of malaria RDT positivity in the intervention versus control fokontany. | Difference in differences (DiD) approach comparing baseline to endline is used to compare the prevalence of malaria RDT positivity in the 2 arms | an average of 1 year | |
Secondary | percent of households visited every two weeks | percent of households visited every two weeks out of the number of the households registered in initial census | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | percent of households gave consent | percent of households that were visited every two weeks and gave consent for the screening during each visit | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | Fever incidence | percent of fever cases out of all individuals screened during each visit | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | Malaria incidence | percent of persons with positive RDT and fever cases out of all individuals screened during each visit | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | fever cases with RDT performed | percent of fever cases with RDT performed | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | RDT-positive persons treated with an ACT | percent of RDT-positive persons treated with an ACT during each visit | The event was assessed up to 30 weeks (15 biweekly visits). | |
Secondary | The change in the prevalence of anemia in women aged between 15 and 49 years old in the intervention versus control fokontany | Difference in differences (DiD) approach comparing baseline to endline is used to compare the prevalence of anemia in the 2 arms | an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |